Law360, New York (October 05, 2012, 1:40 PM ET) -- The European Commission on Friday approved Watson Pharmaceuticals Inc.'s proposed €4.25 billion ($5.2 billion) acquisition of Swiss drugmaker Actavis Group, finding that the merged company will still face a significant number of strong competitors in European drug markets.
Watson's proposed takeover of Actavis would create the third-largest generic pharmaceuticals company in the world with about $8 billion in revenue, and would expand Watson's reach into Russia and Central and Eastern Europe.
The European Commission investigated the possible impacts of the merger on various drugs including antidepressants...
EU OKs $5.2B Watson-Actavis Tie-Up
To view the full article, take a free trial now.
